Los Angeles - (NewMediaWire) - October 12, 2021 - The Schall Law Firm, a national shareholder rights litigation
firm, reminds investors of a class action lawsuit against Sesen
Bio, Inc. (“Sesen Bio” or “the Company”) (NASDAQ: SESN) for violations of §§10(b) and 20(a) of the Securities Exchange Act
of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.
Investors who
purchased the Company's securities between December 21, 2020 and August 17, 2021,
inclusive (the ''Class Period''), are encouraged to contact the firm before October
18, 2021.
If you are a
shareholder who suffered a loss, click here to participate.
We also encourage you
to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite
2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of
charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this
case, has not yet been certified, and until certification occurs, you are not
represented by an attorney. If you choose to take no action, you can remain an
absent class member.
According to the
Complaint, the Company made false and misleading statements to the market.
Sesen Bio’s clinical trial for Vicineum suffered from more than 2,000
violations of trial protocols including 215 “major” violations. Three of the
Company’s clinical investigators were found guilty of "serious
noncompliance," during the clinical trial including "back-dating data.”
The Company’s clinical trials showed that Vicineum leaked into the body leading
to side effects including liver failure. Vicineum was not likely to achieve FDA
approval based on the clinical data that was submitted by the Company. Based on
these facts, the Company’s public statements were false and materially
misleading throughout the class period. When the market learned the truth about
Sesen Bio, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm
represents investors around the world and specializes in securities class
action lawsuits and shareholder rights litigation.
This press release may
be considered Attorney Advertising in some jurisdictions under the applicable
law and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
SOURCE:
The Schall Law Firm